TTK Healthcare Limited — Others, 27-06-2025: Shareholders meeting

TTK Healthcare has announced a board meeting to approve financial results and dividend declaration. The company reported 6% growth in revenue to Rs. 801.49 Cr with a profit before tax of Rs. 108.33 Cr, including exceptional items (Rs. 19.77 Cr profit on sale of leasehold land and Rs. 5.86 Cr write-off of male contraceptives inventory due to USAID order cancellation). Profit after tax rose to Rs. 81.66 Cr against Rs. 62.84 Cr last year. The Board proposes a dividend of Rs. 10 per equity share (100%). Key business segments—Consumer Products, Animal Welfare, Medical Devices, Protective Devices, and Foods—all showed steady growth, supported by new product initiatives, market expansion, and Govt. schemes like Ayushman Bharat. The company strengthened governance with appointment of new independent directors, reappointment of Dr. T T Mukund, and new secretarial and cost auditors. Capex was Rs. 14.33 Cr in FY25; estimated Rs. 10 Cr for FY26. The company maintains low gearing with 2.22% debt-to-capital ratio and strong cash/bank balances of Rs. 785 Cr. No material regulatory or legal risks reported. Operating and financial controls are adequate and no fraud or non-compliance issues, except a delayed appointment of a woman director, settled with exchange fines and waiver request pending. The company continues its commitment to ESG with active CSR spend of Rs. 1.45 Cr and “Great Place to Work” certification. Management foresees a promising outlook for FY26 driven by brand building, product innovations, and exports.